Related Experiment Video
Updated: Feb 11, 2026

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
Published on: March 2, 2011
The generic drug user fee amendments: an economic perspective
Ernst R Berndt1, Rena M Conti2, Stephen J Murphy3
1Department of Applied Economics, Massachusetts Institute of Technology, Sloan School of Management, and National Bureau of Economic Research, Cambridge, Massachusetts, USA.
The Generic Drug User Fee Amendments (GDUFA) program, established in 2012, has led to a more concentrated and foreign generic drug manufacturing market. GDUFA II aimed to reduce entry barriers created by initial user fees.
Area of Science:
- Pharmaceutical Policy
- Health Economics
- Regulatory Affairs
Background:
- The majority of prescription drugs in the US are generic, making their regulation and supply critical.
- The Generic Drug User Fee Amendments (GDUFA I) were enacted in 2012, requiring annual fees from generic manufacturers in exchange for FDA performance goals.
Purpose of the Study:
- To analyze the impact of GDUFA I and II on the generic drug market structure.
- To examine the self-reported data submitted by generic manufacturers under GDUFA legislation.
- To discuss the implications of market concentration and foreign manufacturing for GDUFA II.
Main Methods:
- Analysis of legislative history and fee structures of GDUFA I and GDUFA II.
- Examination of public, self-reported data on domestic and foreign generic drug manufacturing facilities.
- Comparative analysis of market structure before and after GDUFA implementation.
Main Results:
- GDUFA I user fees created barriers to entry and favored established manufacturers.
- Generic drug manufacturing supplying the US market is increasingly concentrated and located abroad.
- GDUFA II introduced changes to user fees to mitigate entry barriers.
Conclusions:
- The structure of generic drug manufacturing has evolved significantly under GDUFA legislation.
- Observed market concentration and foreign dominance have implications for GDUFA II's effectiveness.
- Policy adjustments in GDUFA II were intended to foster a more competitive generic drug market.
Related Concept Videos
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Social Cognitive Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
The Behavioral Perspective on Personality
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

